Mario Cazzola

List of Publications by Year
in descending order

404 papers	11,782 citations	31976 53 h-index	54911 84 g-index
428 all docs	428 docs citations	428 times ranked	8986 citing authors

#	Article	IF	Citations
1	Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews, 2012, 64, 450-504.	16.0	379
2	ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung, 2020, 198, 867-877.	3.3	304
3	The scientific rationale for combining long-acting Î²2-agonists and muscarinic antagonists in COPD. Pulmonary Pharmacology and Therapeutics, 2010, 23, 257-267.	2.6	233
4	Î²₂-Agonist Therapy in Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 690-696.	5.6	221
5	A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest, 2016, 149, 1181-1196.	0.8	206
6	Cardiac Effects of Formoterol and Salmeterol in Patients Suffering from COPD with Preexisting Cardiac Arrhythmias and Hypoxemia. Chest, 1998, 114, 411-415.	0.8	178
7	Prevalence of Comorbidities in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 2010, 80, 112-119.	2.6	163
8	Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?. Respiratory Medicine, 2020, 168, 105996.	2.9	143
9	Î²₂â€adrenoceptor agonists: current and future direction. British Journal of Pharmacology, 2011, 163, 4-17.	5.4	142
10	Influence ofN-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review, 2015, 24, 451-461.	7.1	140
11	The effect of N -acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine, 2016, 117, 190-197.	2.9	136
12	Optimizing drug delivery in COPD: The role of inhaler devices. Respiratory Medicine, 2017, 124, 6-14.	2.9	131
13	Markers of disease severity in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2006, 19, 189-199.	2.6	127
14	The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2004, 17, 35-39.	2.6	126
15	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respiratory Medicine,the, 2013, 1, 714-727.	10.7	121
16	Inhaled ??2-Adrenoceptor Agonists. Drugs, 2005, 65, 1595-1610.	10.9	117
17	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulmonary Pharmacology and Therapeutics, 2016, 40, 95-103.	2.6	112
18	TNF-Î± inhibitors in asthma and COPD: We must not throw the baby out with the bath water. Pulmonary Pharmacology and Therapeutics, 2010, 23, 121-128.	2.6	108

#	Article	IF	Citations
19	Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacological Reviews, 2020, 72, 218-252.	16.0	104
20	Are phosphodiesterase 4 inhibitors just more theophylline?. Journal of Allergy and Clinical Immunology, 2006, 117, 1237-1243.	2.9	102
21	Ultra long-acting Î²2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs, 2005, 14, 775-783.	4.1	101
22	Triple therapy versus single and dual long-acting bronchodilator therapy inÂCOPD: a systematic review and meta-analysis. European Respiratory Journal, 2018, 52, 1801586.	6.7	101
23	Asthma and comorbid medical illness. European Respiratory Journal, 2011, 38, 42-49.	6.7	98
24	Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2012, 21, 101-108.	2.3	97
25	Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. European Journal of Pharmacology, 2015, 761, 168-173.	3.5	97
26	Clinical Pharmacokinetics of Salmeterol. Clinical Pharmacokinetics, 2002, 41, 19-30.	3.5	95
27	A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulmonary Pharmacology and Therapeutics, 2007, 20, 556-561.	2.6	92
28	Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respiratory Medicine, 2012, 106, 249-256.	2.9	89
29	Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends in Pharmacological Sciences, 2011, 32, 495-506.	8.7	84
30	Emerging anti-inflammatory strategies for COPD. European Respiratory Journal, 2012, 40, 724-741.	6.7	84
31	Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 414-423.	2.5	80
32	Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. European Journal of Pharmacology, 2014, 745, 135-143.	3.5	80
33	Inhaled Combination Therapy With Long-Acting Î² 2 -Agonists and Corticosteroids in Stable COPD. Chest, 2004, 126, 220-237.	0.8	77
34	Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 552-563.	1.6	77
35	Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 175-181.	1.6	73
36	Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respiratory Research, 2016, 17, 70.	3.6	71

#	Article	IF	Citations
37	Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2012, 25, 62-68.	2.6	69
38	Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: A pilot study. Respiratory Medicine, 2006, 100, 1925-1932.	2.9	68
39	High Glucose Enhances Responsiveness of Human Airways Smooth Muscle via the Rho/ROCK Pathway. American Journal of Respiratory Cell and Molecular Biology, 2012, 47, 509-516.	2.9	66
40	Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulmonary Pharmacology and Therapeutics, 2013, 26, 307-317.	2.6	65
41	Bronchodilators. Clinics in Chest Medicine, 2014, 35, 191-201.	2.1	65
42	Adding a LAMA to ICS/LABA Therapy. Chest, 2019, 155, 758-770.	0.8	65
43	Adherence to COPD treatment: Myth and reality. Respiratory Medicine, 2017, 129, 117-123.	2.9	64
44	Additive Effects of Salmeterol and Fluticasone or Theophylline in COPD. Chest, 2000, 118, 1576-1581.	0.8	63
45	Severe Asthma and Biological Therapy: When, Which, and for Whom. Pulmonary Therapy, 2020, 6, 47-66.	2.2	63
46	Biomarkers in COPD. Pulmonary Pharmacology and Therapeutics, 2010, 23, 493-500.	2.6	61
47	Oxidation pathway and exacerbations in COPD: the role of NAC. Expert Review of Respiratory Medicine, 2016, 10, 89-97.	2.5	60
48	Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Respiratory Research, 2017, 18, 26.	3.6	60
49	Ultra-Long-Acting ??2-Adrenoceptor Agonists. Drugs, 2007, 67, 503-515.	10.9	57
50	Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Current Opinion in Pharmacology, 2018, 40, 95-103.	3.5	57
51	The prevalence of asthma and COPD in Italy: A practice-based study. Respiratory Medicine, 2011, 105, 386-391.	2.9	55
52	Anti-TNF-Î± and Th1 cytokine-directed therapies for the treatment of asthma. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 43-50.	2.3	54
53	Safety of inhaled corticosteroids: Room for improvement. Pulmonary Pharmacology and Therapeutics, 2007, 20, 23-35.	2.6	54
54	Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. Respiratory Medicine, 2015, 109, 1305-1311.	2.9	54

#	Article	IF	Citations
55	Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 804-814.	2.9	54
56	Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2017, 45, 148-158.	2.6	54
57	Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respiratory Medicine, 2017, 129, 189-198.	2.9	54
58	Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respiratory Medicine, 2005, 99, 524-528.	2.9	53
59	Combination of Formoterol and Tiotropium in the Treatment of COPD: Effects on Lung Function. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 404-415.	1.6	53
60	Comorbidities of asthma. Current Opinion in Pulmonary Medicine, 2013, 19, 36-41.	2.6	53
61	Airflow obstruction: is it asthma or is it COPD?. International Journal of COPD, 2016, Volume 11, 3007-3013.	2.3	52
62	Do we really need asthmaâ€“chronic obstructive pulmonary disease overlap syndrome?. Journal of Allergy and Clinical Immunology, 2016, 138, 977-983.	2.9	52
63	Brain natriuretic peptide: Much more than a biomarker. International Journal of Cardiology, 2016, 221, 1031-1038.	1.7	51
64	TSLP Inhibitors for Asthma: Current Status and Future Prospects. Drugs, 2020, 80, 449-458.	10.9	51
65	LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review, 2017, 26, 160043.	7.1	50
66	Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. British Journal of Pharmacology, 2011, 163, 1740-1754.	5.4	49
67	Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. European Respiratory Journal, 2014, 44, 475-482.	6.7	48
68	A review of the most common patient-reported outcomes in COPD – revisiting current knowledge and estimating future challenges. International Journal of COPD, 2015, 10, 725.	2.3	48
69	Novel bronchodilators in asthma. Current Opinion in Pulmonary Medicine, 2010, 16, 6-12.	2.6	47
70	Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. Pulmonary Pharmacology and Therapeutics, 2015, 31, 123-129.	2.6	47
71	Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. Expert Opinion on Drug Safety, 2016, 15, 1133-1146.	2.4	47
72	Interaction between corticosteroids and muscarinic antagonists in human airways. Pulmonary Pharmacology and Therapeutics, 2016, 36, 1-9.	2.6	47

#	Article	IF	Citations
73	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. British Journal of Pharmacology, 2020, 177, 1150-1163.	5.4	47
74	SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines. Vaccines, 2021, 9, 227.	4.4	47
75	Î±₁-Antitrypsin deficiency and chronic respiratory disorders. European Respiratory Review, 2020, 29, 190073.	7.1	47
76	Defining Phenotypes in COPD: An Aid to Personalized Healthcare. Molecular Diagnosis and Therapy, 2014, 18, 381-388.	3.8	46
77	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2015, 32, 15-23.	2.6	46
78	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends in Pharmacological Sciences, 2017, 38, 940-951.	8.7	46
79	SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. European Respiratory Journal, 2020, 56, 2000625.	6.7	46
80	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respiratory Research, 2019, 20, 104.	3.6	45
81	Prospects for COPD treatment. Current Opinion in Pharmacology, 2021, 56, 74-84.	3.5	45
82	One hundred years of chronic obstructive pulmonary disease (COPD). Respiratory Medicine, 2007, 101, 1049-1065.	2.9	43
83	The use of bronchodilators in the treatment of airway obstruction in elderly patients. Pulmonary Pharmacology and Therapeutics, 2006, 19, 311-319.	2.6	42
84	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends in Pharmacological Sciences, 2019, 40, 452-463.	8.7	42
85	Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respiratory Medicine, 2009, 103, 1592-1613.	2.9	41
86	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. European Respiratory Review, 2018, 27, 180010.	7.1	41
87	Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. Pulmonary Pharmacology and Therapeutics, 2011, 24, 221-226.	2.6	40
88	Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetologica, 2014, 51, 933-940.	2.5	40
89	Onset of Action of Single Doses of Formoterol Administered via Turbuhaler in Patients with Stable COPD. Pulmonary Pharmacology and Therapeutics, 2001, 14, 41-45.	2.6	39
90	Pharmacological modulation of Î²-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulmonary Pharmacology and Therapeutics, 2010, 23, 1-8.	2.6	39

#	Article	IF	Citations
91	The MABA approach: a new option to improve bronchodilator therapy. European Respiratory Journal, 2013, 42, 885-887.	6.7	39
92	The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery, 2016, 11, 733-744.	5.0	39
93	Doxofylline is not just another theophylline!. International Journal of COPD, 2017, Volume 12, 3487-3493.	2.3	39
94	Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 48, 88-96.	2.6	39
95	Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Delivery, 2020, 17, 635-646.	5.0	39
96	Pharmacological Characterization of Adenosine Receptors on Isolated Human Bronchi. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 1222-1231.	2.9	38
97	New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Design, Development and Therapy, 2013, 7, 1201.	4.3	38
98	The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction. Chest, 2002, 121, 230-241.	0.8	37
99	Delivering Antibacterials to the Lungs. Treatments in Respiratory Medicine, 2002, 1, 261-272.	1.2	37
100	Long-acting β₂-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. International Journal of COPD, 2008, Volume 3, 521-529.	2.3	37
101	The Challenges of Precision Medicine in COPD. Molecular Diagnosis and Therapy, 2017, 21, 345-355.	3.8	37
102	Acute exacerbations of COPD: risk factors for failure and relapse. International Journal of COPD, 2017, Volume 12, 2687-2693.	2.3	37
103	Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 20, 291-298.	2.3	36
104	Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opinion on Drug Safety, 2015, 14, 533-541.	2.4	36
105	Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. Pulmonary Pharmacology and Therapeutics, 2015, 31, 68-78.	2.6	36
106	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2016, 76, 1257-1270.	10.9	36
107	Protein Prenylation Contributes to the Effects of LPS on EFSâ€“Induced Responses in Human Isolated Bronchi. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 704-710.	2.9	35
108	PDE inhibitors currently in early clinical trials for the treatment of asthma. Expert Opinion on Investigational Drugs, 2014, 23, 1267-1275.	4.1	35

#	Article	IF	Citations
109	The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. International Journal of COPD, 2017, Volume 12, 3469-3485.	2.3	35
110	Chronic Obstructive Pulmonary Disease and Stroke. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 405-413.	1.6	35
111	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respiratory Medicine, 2019, 154, 86-92.	2.9	35
112	Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respiratory Medicine, 2019, 153, 3-13.	2.9	35
113	Guidance on nebulization during the current COVID-19 pandemic. Respiratory Medicine, 2021, 176, 106236.	2.9	35
114	Immunomodulatory impact of a synbiotic in Th₁and Th₂models of infection. Therapeutic Advances in Respiratory Disease, 2010, 4, 259-270.	2.6	34
115	Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. COPD Research and Practice, 2015, 1, .	0.7	33
116	An update on bronchodilators in Phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2012, 21, 1489-1501.	4.1	32
117	Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2013, 14, 775-781.	1.8	32
118	LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. International Journal of COPD, 2018, Volume 13, 3115-3130.	2.3	32
119	Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101841.	2.6	32
120	Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study. Therapeutic Advances in Respiratory Disease, 2010, 4, 271-278.	2.6	31
121	Acute effects of indacaterol on lung hyperinflation in moderate COPD: A comparison with tiotropium. Respiratory Medicine, 2012, 106, 84-90.	2.9	31
122	Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology, 2015, 761, 383-390.	3.5	31
123	Long acting beta 2 agonists and theophylline in stable chronic obstructive pulmonary disease. Thorax, 1999, 54, 730-736.	5.6	30
124	Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view. Respiratory Medicine, 2008, 102, 321-327.	2.9	30
125	Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. Drugs, 2015, 75, 1575-1585.	10.9	30
126	Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1007-1013.	3.3	30

#	Article	IF	Citations
127	Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respiratory Research, 2018, 19, 65.	3.6	30
128	Multifaceted activity ofN-acetyl-<scp>l</scp>-cysteine in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 693-708.	2.5	30
129	The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: A pilot study. Respiratory Medicine, 2007, 101, 957-962.	2.9	29
130	Treating systemic effects of COPD. Trends in Pharmacological Sciences, 2007, 28, 544-550.	8.7	29
131	Preclinical Evaluation of an Inhibitor of Cytosolic Phospholipase A₂Î± for the Treatment of Asthma. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 656-665.	2.5	29
132	Î²-Adrenoceptor Modulation in Chronic Obstructive Pulmonary Disease: Present and Future Perspectives. Drugs, 2013, 73, 1653-1663.	10.9	29
133	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs, 2017, 77, 721-732.	10.9	29
134	Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Review of Respiratory Medicine, 2021, 15, 143-152.	2.5	29
135	Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulmonary Pharmacology and Therapeutics, 2006, 19, 419-424.	2.6	28
136	Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2013, 14, 2489-2499.	1.8	28
137	Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. Drug Safety, 2016, 39, 501-508.	3.2	28
138	Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. European Journal of Pharmacology, 2017, 812, 147-154.	3.5	28
139	Controversy surrounding the Sputnik V vaccine. Respiratory Medicine, 2021, 187, 106569.	2.9	28
140	Treatments for COPD. Respiratory Medicine, 2005, 99, S28-S40.	2.9	27
141	Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulmonary Pharmacology and Therapeutics, 2009, 22, 478-482.	2.6	27
142	Treatment of COPD: moving beyond the lungs. Current Opinion in Pharmacology, 2012, 12, 315-322.	3.5	27
143	Role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine, 2017, 11, 239-253.	2.5	27
144	Pharmacological treatment and current controversies in COPD. F1000Research, 2019, 8, 1533.	1.6	27

#	Article	IF	Citations
145	Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?. Drugs, 2014, 74, 1983-1992.	10.9	26
146	Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2014, 15, 961-977.	1.8	26
147	Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. Respiratory Medicine, 2016, 117, 150-153.	2.9	26
148	Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. Expert Review of Respiratory Medicine, 2018, 12, 261-264.	2.5	26
149	Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. Expert Opinion on Investigational Drugs, 2019, 28, 827-833.	4.1	26
150	Theophylline in the Inhibition of Angiotensin-Converting Enzyme Inhibitor-Induced Cough. Respiration, 1993, 60, 212-215.	2.6	25
151	Review: Safety of long-acting Î²2 -agonists in the treatment of asthma. Therapeutic Advances in Respiratory Disease, 2007, 1, 35-46.	2.6	25
152	Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs of Today, 2010, 46, 139.	1.1	25
153	Tiotropium formulations and safety: a network meta-analysis. Therapeutic Advances in Drug Safety, 2017, 8, 17-30.	2.4	25
154	Tremor and Î²2-adrenergic agents: Is it a real clinical problem?. Pulmonary Pharmacology and Therapeutics, 2012, 25, 4-10.	2.6	24
155	Muscarinic Receptor Antagonists. Handbook of Experimental Pharmacology, 2016, 237, 41-62.	1.8	24
156	How does race/ethnicity influence pharmacological response to asthma therapies?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 435-446.	3.3	24
157	The future of bronchodilation: looking for new classes of bronchodilators. European Respiratory Review, 2019, 28, 190095.	7.1	24
158	Longâ€acting muscarinic antagonists and small airways in asthma: Which link?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1990-2001.	5.7	24
159	Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Targets, 2007, 11, 1273-1286.	3.4	23
160	Primary care of the patient with chronic obstructive pulmonary disease in Italy. Respiratory Medicine, 2009, 103, 582-588.	2.9	23
161	Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation . International Journal of COPD, 2019, Volume 14, 2733-2744.	2.3	23
162	Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review. Respiratory Medicine, 2020, 171, 106114.	2.9	23

#	Article	IF	Citations
163	Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opinion on Pharmacotherapy, 2020, 21, 2305-2316.	1.8	23
164	Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. Therapeutic Advances in Respiratory Disease, 2009, 3, 59-63.	2.6	22
165	Emerging drugs for chronic obstructive pulmonary disease. Expert Opinion on Emerging Drugs, 2012, 17, 61-82.	2.4	22
166	Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit. Respiratory Medicine, 2013, 107, 1417-1422.	2.9	22
167	Cardiovascular disease in patients with COPD. Lancet Respiratory Medicine,the, 2015, 3, 593-595.	10.7	22
168	Comparative Effects of a Two-Week Treatment with Nebivolol and Nifedipine in Hypertensive Patients Suffering from COPD. Respiration, 2004, 71, 159-164.	2.6	21
169	The effect of indacaterol during an acute exacerbation of COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 630-634.	2.6	21
170	Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk ofÂcoronary artery disease in COPD patients. Respiratory Medicine, 2015, 109, 1019-1025.	2.9	21
171	Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and) Tj ETQq1 1 0.784314 rgBT /Overlock 1	2.6	21
172	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2019, 56, 39-50.	2.6	21
173	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs, 2020, 80, 1799-1809.	10.9	21
174	Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opinion on Pharmacotherapy, 2010, 11, 441-449.	1.8	20
175	IL-17 in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2012, 6, 135-138.	2.5	20
176	Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. Current Opinion in Pharmacology, 2012, 12, 300-308.	3.5	20
177	Project PriMo: Sharing principles and practices of bronchodilator therapy monitoring in COPD. Pulmonary Pharmacology and Therapeutics, 2013, 26, 218-228.	2.6	20
178	Brain Natriuretic Peptide Protects against Hyperresponsiveness of Human Asthmatic Airway Smooth Muscle via an Epithelial Cellâ€“Dependent Mechanism. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 493-501.	2.9	20
179	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. Life Sciences, 2015, 131, 44-50.	4.3	20
180	Bifunctional Drugs for the Treatment of Respiratory Diseases. Handbook of Experimental Pharmacology, 2016, 237, 197-212.	1.8	20

#	Article	IF	Citations
181	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 48, 185-194.	2.6	20
182	N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. Biomedicine and Pharmacotherapy, 2018, 103, 1-8.	5.6	20
183	Long-Acting Bronchodilators Are the First-Choice Option for the Treatment of Stable COPD. Chest, 2004, 125, 9-11.	0.8	19
184	Doppler echocardiographic assessment of the effects of inhaled long-acting Î²2-agonists on pulmonary artery pressure in COPD patients. Pulmonary Pharmacology and Therapeutics, 2007, 20, 258-264.	2.6	19
185	Use of 6-min and 12-min walking test for assessing the efficacy of formoterol in COPD. Respiratory Medicine, 2008, 102, 1425-1430.	2.9	19
186	Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: A pilot study. Respiratory Medicine, 2010, 104, 412-417.	2.9	19
187	Triple combinations in chronic obstructive pulmonary disease â€“ is three better than two?. Expert Opinion on Pharmacotherapy, 2014, 15, 2475-2478.	1.8	19
188	Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation). Pulmonary Pharmacology and Therapeutics, 2015, 33, 75-80.	2.6	19
189	Long-acting Î²2 agonists as potential option in the treatment of acute exacerbations of COPD. Pulmonary Pharmacology and Therapeutics, 2003, 16, 197-201.	2.6	18
190	Macrolide and occult infection in asthma. Current Opinion in Pulmonary Medicine, 2004, 10, 7-14.	2.6	18
191	Î²-Blockers Are Safe in Patients with Chronic Obstructive Pulmonary Disease, But Only with Caution. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 661-662.	5.6	18
192	Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?. Expert Opinion on Investigational Drugs, 2018, 27, 573-581.	4.1	18
193	Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. Advances in Therapy, 2019, 36, 3291-3298.	2.9	18
194	A potential role of triple therapy for asthma patients. Expert Review of Respiratory Medicine, 2019, 13, 1079-1085.	2.5	18
195	The effective treatment of COPD: Anticholinergics and what else?. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 277-286.	0.5	17
196	Tiotropium is less likely to induce oxygen desaturation in stable COPD patients compared to long-acting Î²2-agonists. Respiratory Medicine, 2007, 101, 1798-1803.	2.9	17
197	The cardiovascular risk of tiotropium: is it real?. Expert Opinion on Drug Safety, 2010, 9, 783-792.	2.4	17
198	Novel glucocorticoid receptor agonists in the treatment of asthma. Expert Opinion on Investigational Drugs, 2015, 24, 1473-1482.	4.1	17

#	Article	IF	Citations
199	Fixed-Dose Combination Inhalers. Handbook of Experimental Pharmacology, 2016, 237, 117-129.	1.8	17
200	Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 526-532.	1.6	17
201	Impact of doxofylline in COPD: A pairwise meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 51, 1-9.	2.6	17
202	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. Monaldi Archives for Chest Disease, 2018, 88, 886.	0.6	17
203	The latest on the role of LAMAs in asthma. Journal of Allergy and Clinical Immunology, 2020, 146, 1288-1291.	2.9	17
204	The effect of doxofylline in asthma and COPD. Respiratory Medicine, 2020, 164, 105904.	2.9	17
205	Treatable Mechanisms in Asthma. Molecular Diagnosis and Therapy, 2021, 25, 111-121.	3.8	17
206	New Avenues for Phosphodiesterase Inhibitors in Asthma. Journal of Experimental Pharmacology, 2021, Volume 13, 291-302.	3.2	17
207	Preexisting cardiorespiratory comorbidity does not preclude the success of multidisciplinary rehabilitation in post-COVID-19 patients. Respiratory Medicine, 2021, 184, 106470.	2.9	17
208	Application of Number Needed to Treat (NNT) as a Measure of Treatment Effect in Respiratory Medicine. Treatments in Respiratory Medicine, 2006, 5, 79-84.	1.4	16
209	Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respiratory Medicine, 2013, 107, 848-853.	2.9	16
210	Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2014, 8, 665-671.	2.5	16
211	Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101828.	2.6	16
212	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101855.	2.6	16
213	Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review . Journal of Experimental Pharmacology, 2020, Volume 12, 233-253.	3.2	16
214	Sex differences in COPD management. Expert Review of Clinical Pharmacology, 2021, 14, 323-332.	3.1	16
215	Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung, 2021, 199, 335-343.	3.3	16
216	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 129-137.	3.3	15

#	Article	IF	Citations
217	N-acetylcysteine in COPD may be beneficial, but for whom?. Lancet Respiratory Medicine,the, 2014, 2, 166-167.	10.7	15
218	An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network. International Journal of Mycobacteriology, 2016, 5, 244-247.	0.6	15
219	Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opinion on Drug Safety, 2018, 17, 429-435.	2.4	15
220	Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy, 2019, 23, 603-614.	3.8	15
221	Ultra-LABAs for the treatment of asthma. Respiratory Medicine, 2019, 156, 47-52.	2.9	15
222	A review of the pharmacokinetics of M3 muscarinic receptor antagonists used for the treatment of asthma. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 143-148.	3.3	15
223	Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2013, 14, 1205-1214.	1.8	14
224	Influence of ethnicity on response to asthma drugs. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1089-1097.	3.3	14
225	QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 1079-1090.	1.8	14
226	COPD: the patient perspective. International Journal of COPD, 2016, 11 Spec Iss, 13.	2.3	14
227	An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations?. Expert Review of Respiratory Medicine, 2018, 12, 43-54.	2.5	14
228	The role of combination therapy with corticosteroids and long-acting ï¿½2-agonists in the prevention of exacerbations in COPD. International Journal of COPD, 2006, 1, 345-354.	2.3	14
229	Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulmonary Pharmacology and Therapeutics, 2009, 22, 177-182.	2.6	13
230	Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 50, 28-37.	2.6	13
231	The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety, 2018, 17, 589-596.	2.4	13
232	Ensifentrine (RPL554): an inhaled â€˜bifunctionalâ€™ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharmaceutical Patent Analyst, 2018, 7, 249-257.	1.1	13
233	Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2019, 20, 737-750.	1.8	13
234	The role of indacaterol for chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2013, 5, 559-66.	1.4	13

#	Article	IF	Citations
235	Parenteral Antibiotic Therapy in the Treatment of Lower Respiratory Tract Infections. Strategies to Minimize the Development of Antibiotic Resistance. Pulmonary Pharmacology and Therapeutics, 2000, 13, 249-256.	2.6	12
236	Bronchodilator therapy for chronic cough. Pulmonary Pharmacology and Therapeutics, 2017, 47, 88-92.	2.6	12
237	POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. Chest, 2018, 154, 746-748.	0.8	12
238	Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells. European Journal of Pharmacology, 2018, 832, 114-119.	3.5	12
239	Bronchodilators in subjects with asthma-related comorbidities. Respiratory Medicine, 2019, 151, 43-48.	2.9	12
240	Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease . Journal of Experimental Pharmacology, 2020, Volume 12, 559-574.	3.2	12
241	Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis. Drugs, 2022, 82, 1-13.	10.9	12
242	COVIDâ€19Â vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€”EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	5.7	12
243	Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Current Opinion in Investigational Drugs, 2009, 10, 482-90.	2.3	12
244	Pharmacodynamics of Levofloxacin in Patients With Acute Exacerbation of Chronic Bronchitis. Chest, 2005, 128, 2093-2098.	0.8	11
245	Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. Respiratory Medicine, 2005, 99, 663-669.	2.9	11
246	A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD. Pulmonary Pharmacology and Therapeutics, 2009, 22, 522-525.	2.6	11
247	Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation. Respiratory Medicine, 2021, 182, 106401.	2.9	11
248	The 5T approach in asthma: Triple Therapy Targeting Treatable Traits. Respiratory Medicine, 2022, 200, 106915.	2.9	11
249	Potential genetic influences on the response to asthma treatment. Pulmonary Pharmacology and Therapeutics, 2004, 17, 253-261.	2.6	10
250	Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respiratory Medicine, 2013, 107, 107-111.	2.9	10
251	Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2015, 8, 529-539.	3.1	10
252	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1101-1111.	3.3	10

#	Article	IF	Citations
253	Varenicline for long term smoking cessation in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2018, 53, 116-120.	2.6	10
254	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. Multidisciplinary Respiratory Medicine, 2019, 14, 25.	1.5	10
255	Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Review of Clinical Pharmacology, 2020, 13, 977-990.	3.1	10
256	Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert Opinion on Pharmacotherapy, 2021, 22, 611-620.	1.8	10
257	An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. Biologics: Targets and Therapy, 2021, Volume 15, 363-374.	3.2	10
258	Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. Monaldi Archives for Chest Disease, 2022, , .	0.6	10
259	Can FeNO be a biomarker in the post-COVID-19 patients monitoring?. Respiratory Medicine, 2022, 193, 106745.	2.9	10
260	Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology, 2022, 88, 3657-3673.	2.4	10
261	Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Pulmonary Pharmacology and Therapeutics, 2003, 16, 105-109.	2.6	9
262	It's about time â€“ directing our attention toward modifying the course of COPD. Respiratory Medicine, 2008, 102, S37-S48.	2.9	9
263	Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2011, 24, 118-122.	2.6	9
264	LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients. Evidence-Based Medicine, 2016, 21, 222-222.	0.6	9
265	Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2016, 17, 977-988.	1.8	9
266	An update on the pharmacotherapeutic management of lower respiratory tract infections. Expert Opinion on Pharmacotherapy, 2017, 18, 973-988.	1.8	9
267	Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 239-245.	3.3	9
268	Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. Npj Primary Care Respiratory Medicine, 2018, 28, 10.	2.6	9
269	An inhaled â€œbifunctionalâ€•dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. European Respiratory Journal, 2018, 52, 1801675.	6.7	9
270	Step-up and step-down approaches in the treatment of asthma. Expert Review of Respiratory Medicine, 2021, 15, 1159-1168.	2.5	9

#	Article	IF	Citations
271	SMART for the treatment of asthma: A network meta-analysis of real-world evidence. Respiratory Medicine, 2021, 188, 106611.	2.9	9
272	New Treatments for COPD in the Elderly. Current Pharmaceutical Design, 2014, 20, 5968-5982.	1.9	9
273	Beyond Dual Bronchodilation â€“ Triple Therapy, When and Why. International Journal of COPD, 2022, Volume 17, 165-180.	2.3	9
274	Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. Respiratory Medicine, 2008, 102, 815-818.	2.9	8
275	Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. Expert Opinion on Drug Discovery, 2014, 9, 595-607.	5.0	8
276	Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology, 2015, 8, 35-41.	3.1	8
277	The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BioMed Research International, 2016, 2016, 1-7.	1.9	8
278	Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting Î²-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses. Pulmonary Therapy, 2019, 5, 117-126.	2.2	8
279	Cardiovascular Disease in Chronic Respiratory Disorders and Beyond. Journal of the American College of Cardiology, 2019, 73, 2178-2180.	2.8	8
280	Emerging muscarinic receptor antagonists for the treatment of asthma. Expert Opinion on Emerging Drugs, 2020, 25, 123-130.	2.4	8
281	Classes of drugs that target the cellular components of inflammation under clinical development for COPD. Expert Review of Clinical Pharmacology, 2021, 14, 1015-1027.	3.1	8
282	The future of inhalation therapy in chronic obstructive pulmonary disease. Current Research in Pharmacology and Drug Discovery, 2022, 3, 100092.	3.6	8
283	Onset of Action of Formoterol versus Salmeterol via Dry Powder Inhalers in Moderate Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation, 2012, 32, 147-155.	2.2	7
284	Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. International Journal of COPD, 2015, 10, 1383.	2.3	7
285	Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol. Therapeutics and Clinical Risk Management, 2015, 11, 1805.	2.0	7
286	Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 791-793.	3.8	7
287	Onset of action of budesonide/formoterol SpiromaxÂ® compared with budesonide/formoterol TurbuhalerÂ® in patients with COPD. Pulmonary Pharmacology and Therapeutics, 2016, 39, 48-53.	2.6	7
288	Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 813-822.	3.3	7

#	Article	IF	Citations
289	Is ICSâ€“LAMA an alternative option to treat patients with COPD?. Lancet Respiratory Medicine,the, 2018, 6, 316-317.	10.7	7
290	A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101883.	2.6	7
291	A case scenario study on adherence to COPD GOLD recommendations by general practitioners in a rural area of southern Italy: The â€œprogetto PADREâ€•. Respiratory Medicine, 2020, 170, 105985.	2.9	7
292	The role of triple therapy in the management of COPD. Expert Review of Clinical Pharmacology, 2020, 13, 865-874.	3.1	7
293	Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opinion on Drug Delivery, 2021, 18, 891-906.	5.0	7
294	Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102050.	2.6	7
295	Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis. Cells, 2022, 11, 1797.	4.1	7
296	To Add, or Not To Add an Inhaled Corticosteroid in Moderate COPD. Chest, 2008, 134, 223-225.	0.8	6
297	The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2010, 4, 195-198.	2.6	6
298	Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 107-115.	1.8	6
299	Dual bronchodilation and exacerbations of COPD. Journal of Thoracic Disease, 2016, 8, 2383-2386.	1.4	6
300	Pharmacogenetic and pharmacogenomic considerations of asthma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1159-1167.	3.3	6
301	A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opinion on Drug Safety, 2018, 17, 509-517.	2.4	6
302	Combining Dual Bronchodilation and Î²-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. Chest, 2018, 153, 1289-1291.	0.8	6
303	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. Journal of Clinical Medicine, 2020, 9, 2397.	2.4	6
304	Pharmacological management of adult patients with acute respiratory distress syndrome. Expert Opinion on Pharmacotherapy, 2020, 21, 2169-2183.	1.8	6
305	Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 261-271.	0.7	6
306	New perspectives on the role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine, 2020, 14, 817-824.	2.5	6

#	Article	IF	Citations
307	Benralizumab for the treatment of asthma. Drugs of Today, 2017, 53, 633.	1.1	6
308	Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile. Journal of Asthma and Allergy, 2022, Volume 15, 565-577.	3.4	6
309	One hundred years of respiratory medicine chronic obstructive pulmonary disease (COPD)â€"Republished article. Respiratory Medicine: COPD Update, 2008, 4, 8-25.	0.0	5
310	Arformoterol tartrate in the treatment of COPD. Expert Review of Respiratory Medicine, 2010, 4, 155-162.	2.5	5
311	Energy expenditure and impact of bronchodilators in COPD patients. Respiratory Medicine, 2010, 104, 1490-1494.	2.9	5
312	The clinical use of regenerative therapy in COPD. International Journal of COPD, 2014, 9, 1389.	2.3	5
313	Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respiratory Medicine, 2014, 108, 307-313.	2.9	5
314	Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2015, 9, 5-12.	2.5	5
315	Combination treatment in asthma: Reviewing old and new options. Pulmonary Pharmacology and Therapeutics, 2015, 34, 72-74.	2.6	5
316	Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research, 2017, 6, 627-636.	1.4	5
317	Assessing the viability of long-acting Î²₂-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 129-136.	3.3	5
318	Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opinion on Pharmacotherapy, 2018, 19, 2043-2053.	1.8	5
319	New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. International Journal of COPD, 2018, Volume 13, 2805-2819.	2.3	5
320	Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD). Expert Opinion on Investigational Drugs, 2020, 29, 723-738.	4.1	5
321	Is it time to look beyond bronchodilators and corticosteroids in treating COPD?. Future Drug Discovery, 2021, 3, FDD61.	2.1	5
322	Long-acting Î²₂agonists in asthma and allergic rhinitis. Expert Opinion on Pharmacotherapy, 2008, 9, 1531-1539.	1.8	4
323	Olodaterol for the treatment of asthma. Expert Opinion on Investigational Drugs, 2016, 25, 861-866.	4.1	4
324	Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. Respiration, 2021, 100, 93-95.	2.6	4

#	Article	IF	Citations
325	Management of COPD patients during COVID: difficulties and experiences. Expert Review of Respiratory Medicine, 2021, 15, 1025-1033.	2.5	4
326	The Future of Bronchodilators in COPD and Asthma. Archivos De Bronconeumologia, 2022, 58, 107-108.	0.8	4
327	Disputes over the production and dissemination of misinformation in the time of COVID-19. Respiratory Medicine, 2021, 182, 106380.	2.9	4
328	Reply to Han et al.: impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile. Expert Review of Respiratory Medicine, 2021, 15, 579-581.	2.5	4
329	An Obvious Paradigm. Chest, 2021, 160, 1157-1159.	0.8	4
330	Impact of long-acting muscarinic antagonists on small airways in asthma and COPD: A systematic review. Respiratory Medicine, 2021, 189, 106639.	2.9	4
331	Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma. US Respiratory & Pulmonary Diseases, 2020, 5, 18.	0.2	4
332	Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today?. Expert Opinion on Pharmacotherapy, 2022, 23, 917-927.	1.8	4
333	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert Opinion on Pharmacotherapy, 2022, 23, 1205-1216.	1.8	4
334	Cough and asthma: the role of inhaled corticosteroids and ÃŸ2-agonists. Therapeutic Advances in Respiratory Disease, 2008, 2, 7-11.	2.6	3
335	From large clinical trials to management of COPD in the real world. Therapeutic Advances in Respiratory Disease, 2009, 3, 39-46.	2.6	3
336	Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling. Expert Review of Respiratory Medicine, 2011, 5, 623-625.	2.5	3
337	Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. Current Opinion in Pharmacology, 2012, 12, 225-228.	3.5	3
338	Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease. International Journal of COPD, 2016, 11, 73.	2.3	3
339	In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV1than long-acting beta-agonists plus inhaled corticosteroids. Evidence-Based Medicine, 2017, 22, 183-184.	0.6	3
340	Comparative studies of dual bronchodilation in COPD. Monaldi Archives for Chest Disease, 2021, 91, .	0.6	3
341	Editorial overview: Respiratory: Pulmonary pharmacologyâ€“The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. Current Opinion in Pharmacology, 2021, 60, 54-58.	3.5	3
342	Moving to a Personalized Approach in Respiratory Medicine. From Academic Research to Regulatory Intervention. Frontiers in Drug Safety and Regulation, 2021, 1, .	1.8	3

#	Article	IF	Citations
343	Inhaled medication: which device for which patient?. , 0, , 213-223.		3
344	Medical knowledge about COVID-19 is travelling at the speed of mistrust: why this is relevant to primary care. Family Practice, 2022, 39, 988-991.	1.9	3
345	Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. Immunology and Allergy Clinics of North America, 2022, , .	1.9	3
346	Olodaterol + tiotropium bromide for the treatment of COPD. Expert Review of Respiratory Medicine, 2016, 10, 379-386.	2.5	2
347	Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy, 2017, 3, 45-57.	2.2	2
348	Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 49, 20-26.	2.6	2
349	Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opinion on Emerging Drugs, 2018, 23, 185-199.	2.4	2
350	Indacaterol/Glycopyrronium in Clinical Practice: The Italian Experience. Respiration, 2018, 95, 1-2.	2.6	2
351	Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions. ERJ Open Research, 2020, 6, 00279-2020.	2.6	2
352	Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. Expert Review of Respiratory Medicine, 2020, 14, 621-635.	2.5	2
353	Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 215-223.	1.6	2
354	Comments on â€œPreventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultationsâ€•by Dâ€™Amato et al.. Multidisciplinary Respiratory Medicine, 2021, 16, 757.	1.5	2
355	Bronchodilators for Airway Disease. , 2022, , 712-728.		2
356	As needed therapies in mild to severe asthma: a systematic review and network meta-analysis. , 2020, , .		2
357	Molecular aspects of asthma. Molecular Aspects of Medicine, 2022, 85, 101087.	6.4	2
358	Bronchodilators in bronchiectasis: there is light but it is still too dim. European Respiratory Journal, 2022, 59, 2103127.	6.7	2
359	COPD Identification By The Analysis Of Breath With An Electronic Nose. , 2011, , .		1
360	Lung Blood Flow Must Be Considered When Prescribing a Long-Acting Î² 2 -Agonist/Inhaled Corticosteroid Combination. Chest, 2012, 141, 1134-1136.	0.8	1

#	Article	IF	Citations
361	Rebuttal From Drs Cazzola and Matera. Chest, 2018, 154, 751-752.	0.8	1
362	Tiotropium could provide benefits in the early stage of COPD, but further studies are needed. BMJ Evidence-Based Medicine, 2018, 23, 183-184.	3.5	1
363	Editorial overview: Respiratory: Pulmonary pharmacology â€“ It is time for a breath of fresh air. Current Opinion in Pharmacology, 2018, 40, iv-viii.	3.5	1
364	Response. Chest, 2019, 155, 1079-1080.	0.8	1
365	Brensocatib. Dipeptidyl peptidase 1 (DPP1) inhibitor, Treatment of non-cystic fibrosis bronchiectasis. Drugs of the Future, 2021, 46, 359.	0.1	1
366	Clinical synergism of LABA/LAMA combinations in COPD patients. , 2017, , .		1
367	Impact of doxofylline in COPD: a pair-wise meta-analysis. , 2018, , .		1
368	Efficacy of erdosteine, carbocysteine, and N-acetylcysteine in COPD: a comparative analysis. , 2019, , .		1
369	IND/GLY/MF: synergism in medium and small human hyperresponsive airways. , 2020, , .		1
370	Longâ€'term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved. Polish Archives of Internal Medicine, 2018, 128, 895-897.	0.4	1
371	Efficacy and safety profile of xanthines in COPD: a network meta-analysis. , 2018, , .		1
372	Ensifentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis. Drugs of the Future, 2019, 44, 845.	0.1	1
373	Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. , 2019, , .		1
374	Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination. , 2019, , .		1
375	Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. , 2020, , 238-250.		1
376	Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits. , 2020, , 66-81.		1
377	Advances in the Pharmacological Management of Pediatric Acute Respiratory Distress Syndrome. Expert Opinion on Pharmacotherapy, 2022, 23, 349-360.	1.8	1
378	Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?. US Respiratory & Pulmonary Diseases, 2021, 6, 31.	0.2	1

#	Article	IF	Citations
379	General Pharmacological Considerations in Antibiotic Treatment of Community-Acquired Pneumonia. , 0, , 127-152.		0
380	Omalizumab: Stepping Outside Our Comfort Zone to Broaden the Number of Those Who Can Benefit. Drugs, 2014, 74, 535-537.	10.9	0
381	Introducing COPD Research and Practice. COPD Research and Practice, 2015, 1, .	0.7	0
382	Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. Expert Review of Clinical Pharmacology, 2016, 9, 771-777.	3.1	0
383	Bronchodilator Response as a Possible Predictor of Lung Function Improvement After Pulmonary Rehabilitation in Post-COVID-19 Patients. Archivos De Bronconeumologia, 2021, , .	0.8	0
384	LABA/LAMA combination, exercise and lung hyperinflation in COPD: a meta-analysis. , 2017, , .		0
385	Interaction between tiotropium bromide and olodaterol in human bronchial smooth muscle. , 2017, , .		0
386	N-Acetylcysteine protects human bronchi via inhibiting neurokinin A. , 2017, , .		0
387	Interaction between tiotropium bromide and olodaterol in small human airways. , 2017, , .		0
388	Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis. , 2018, , .		0
389	Impact of glucagon-like peptide 1 receptor agonists on lung function of diabetic patients: a 52 weeks clinical trial. , 2018, , .		0
390	Synergistic interaction between beclomethasone diproprionate and formoterol fumarate in an ex vivo model of bronchial asthma. , 2018, , .		0
391	Mechanisms leading to the bronchoprotective effects of N-Acetylcysteine in human bronchi stimulated by lipopolysaccharide. , 2018, , .		0
392	Long-acting bronchodilators and synergistic interaction: a challenge across the currently available LABA/LAMA combinations. , 2018, , .		0
393	Prevalence and clinical relevance of comorbidities in IPF. , 2018, , .		0
394	Systemic pharmacotherapy. , 2019, , 215-222.		0
395	A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma. , 2019, , .		0
396	Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma. , 2019, , .		0

#	Article	IF	Citations
397	Beclomethasone, formoterol and glycopyrronium: synergism of triple therapy on human airways. , 2019, , .		0
398	Bidimensional comparative analysis of LABA/LAMA FDCs in COPD. , 2019, , .		0
399	Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma. , 2019, , .		0
400	Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis. , 2019, , .		0
401	Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients. , 2020, , .		0
402	Indacaterol/mometasone furoate combination: synergism in human hyperresponsive airway smooth muscle. , 2020, , .		0
403	Beclomethasone, formoterol and glycopyrronium: effect on an ex vivo model of COPD exacerbation. , 2020, , .		0
404	A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology, 2022, 15, 269-283.	3.1	0